ArticleEULAR rheumatology open2026
Systematic literature review informing the 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis: focus on referral and diagnosis.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to systematically review the literature on polymyalgia rheumatica (PMR) and large vessel vasculitis (LVV) referral and diagnosis to inform the 2025 European Alliance of Associations for Rheumatology recommendations on the management of PMR and primary LVV. Methods: A systematic literature review focused on referral and diagnosis of PMR, giant cell arteritis (GCA), and Takayasu arteritis (TAK) was conducted across MEDLINE, Embase, and Cochrane for randomised trials, observational studies, and systematic reviews published from April 1, 2014 for PMR, and January 1, 2018 for LVV, to 31 December, 2024. Results: Forty-one studies were included, all of which were observational. Fast-track clinics for suspected PMR shortened the time to diagnosis (80-53 days and 12-7 days, 2 studies, Conclusions: Initial evidence on fast-track clinics emerged in PMR. Subclinical LVV with PMR-like presentation is increasingly recognised, but its long-term prognosis remains unclear. The value of multimodal diagnostic approaches has been shown in GCA; studies are lacking in TAK and PMR.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.